Product Code: GVR-2-68038-646-2
The global cancer immunotherapy drug discovery outsourcing market size is projected to reach USD 1.7Billion by 2025, according to a new report by Grand View Research, Inc., rising at a CAGR of 13.5% during the forecast period. Increasing prevalence of cancer and rising mortality associated with cancer, along with growing development in the field of cancer immunotherapy, are anticipated to stimulate the growth of the market.
In order to maintain pace with increasing competition in the cancer therapeutics industry, pharmaceutical companies spend 2.5% more than other high tech industries in the in-house R&D. Hence, they are swiftly shifting towards outsourcing of drug discovery in order to achieve lower in-house R&D costs.
Additionally, favorable tax credit allows pharmaceutical companies to appropriately plan their global projects with a reputed CRO and therefore, receive benefits and reduce problems associated with taxation authorities or other bodies administering such incentive programs.
Several new molecules for cancer immunotherapy and new immunotherapeutic options, such as tumor infiltrating lymphocytes, check point inhibitors immunomodulators, and CAR-T cell therapy, have been introduced. Some are in the pipeline and are being tested for their ability to provide better cancer treatment
Further key findings from the study suggest:
Monoclonal antibodies emerged as the largest segment in 2017 because of increasing regulatory approvals and higher efficacy
Target identification and validation accounted for the largest share in the global market owing to higher costs incurred and increased investments in new drug development
North America dominated the market with the largest share in 2017. Rising incidence of cancer and increasing demand for novel technologies are facilitating the dominance of the region during the forecast period
Some of the key players are Covance, Inc.; Explicyte; Aquila BioMedical; Horizon Discovery Group PLC; Crown Bioscience, Inc.; Promega Corporation; HD Biosciences Co., Ltd.; BPS Bioscience, Inc.; Genscript Biotech Corporation; DiscoverX Corporation; Celentyx Ltd.; ImmunXperts SA; Personalis, Inc.; STC Biologics; and Molecular Imaging, Inc. dominated the cancer immunotherapy drug discovery outsourcing market.
Table of Contents
Chapter 1 Methodology and Scope
- 1.1 Research Methodology
- 1.2 Research Scope and Assumptions
Chapter 2 Executive Summary
Chapter 3 Market Variables, Trends & Scope
Chapter 4 Industry Outlook
- 4.1 Market Variable Analysis
- 4.1.1 Increasing in-house R & D costs
- 4.1.2 Increasing adoption of advanced technologies
- 4.1.3 Mergers and acquisitions
- 4.1.4 Tax credit
- 4.2 Market Restraint Analysis
- 4.2.1 Quality issues involved with drug discovery cro services
- 4.2.2 Intellectual property right issues
- 4.3 Porter's Five Forces Analysis
Chapter 5 Drug Type Business Analysis
- 5.1 Cancer Immunotherapy Drug Discovery Outsourcing Market: Drug Movement Analysis
- 5.2 Monoclonal Antibodies
- 5.2.1 Monoclonal antibodies market estimates and forecast, 2014 - 2025
- 5.3 Immunomodulators
- 5.3.1 Immunomodulators market estimates and forecast, 2014 - 2025
- 5.4 Cancer Vaccines and Oncolytic Therapies
- 5.4.1 Cancer vaccines and oncolytic therapies market estimates and forecast, 2014 - 2025
- 5.5 Others
- 5.5.1 Others market estimates and forecast, 2014 - 2025
Chapter 6 Service Business Analysis
- 6.1 Cancer Immunotherapy Drug Discovery Outsourcing Market: service Movement Analysis
- 6.2 Target Identification and Validation
- 6.2.1 Target identification and validation market estimates and forecast, 2014 - 2025
- 6.3 Lead screening and Characterization
- 6.3.1 Lead screening and characterization market estimates and forecast, 2014 - 2025
- 6.4 Cell based Assays
- 6.4.1 Cell based assays market estimates and forecast, 2014 - 2025
Chapter 7 Cancer Business Analysis
- 7.1 Cancer Immunotherapy Drug Discovery Outsourcing Market: Cancer Movement Analysis
- 7.2 Lung Cancer
- 7.2.1 Lung cancer market estimates and forecast, 2014 - 2025
- 7.3 Breast Cancer
- 7.3.1 Breast cancer market estimates and forecast, 2014 - 2025
- 7.4 Colorectal Cancer
- 7.4.1 Colorectal cancer market estimates and forecast, 2014 - 2025
- 7.5 Melanoma
- 7.5.1 Melanoma market estimates and forecast, 2014 - 2025
- 7.6 Prostate Cancer
- 7.6.1 Prostate cancer market estimates and forecast, 2014 - 2025
- 7.7 Head and Neck Cancer
- 7.7.1 Head and neck cancer market estimates and forecast, 2014 - 2025
- 7.8 Ovarian Cancer
- 7.8.1 Ovarian cancer market estimates and forecast, 2014 - 2025
- 7.9 Pancreatic Cancer
- 7.9.1 Pancreatic cancer market estimates and forecast, 2014 - 2025
Chapter 8 Regional Business Analysis
- 8.1 Cancer Immunotherapy Drug Discovery Outsourcing Market: Regional Movement Analysis
- 8.2 North America
- 8.2.1 North America market estimates and forecast, 2014 - 2025
- 8.2.2 U.S.
- 8.2.2.1 U.S. market estimates and forecast, 2014 - 2025
- 8.2.3 Canada
- 8.2.3.1 Canada market estimates and forecast, 2014 - 2025
- 8.3 Europe
- 8.3.1 Europe market estimates and forecast, 2014 - 2025
- 8.3.2 Germany
- 8.3.2.1 Germany market estimates and forecast, 2014 - 2025
- 8.3.3 UK
- 8.3.3.1 UK market estimates and forecast, 2014 - 2025
- 8.4 Asia Pacific
- 8.4.1 Asia Pacific market estimates and forecast, 2014 - 2025
- 8.4.2 India
- 8.4.2.1 India market estimates and forecast, 2014 - 2025
- 8.4.3 China
- 8.4.3.1 China market estimates and forecast, 2014 - 2025
- 8.5 Latin America
- 8.5.1 Latin america market estimates and forecast, 2014 - 2025
- 8.5.2 Brazil
- 8.5.2.1 Brazil market estimates and forecast, 2014 - 2025
- 8.5.3 Mexico
- 8.5.3.1 Mexico market estimates and forecast, 2014 - 2025
- 8.6 Middle East & Africa
- 8.6.1 Middle east and africa market estimates and forecast, 2014 - 2025
- 8.6.2 South Africa
- 8.6.2.1 South Africa market estimates and forecast, 2014 - 2025
Chapter 9 Company Profile
- 9.1 Strategy Framework
- 9.2 Explicit Immuno-Oncology
- 9.2.1 Company overview
- 9.2.2 SWOT analysis
- 9.2.3 Product benchmarking
- 9.2.4 Strategic initiatives
- 9.3 Aquila Biomedical
- 9.3.1 Company overview
- 9.3.2 SWOT analysis
- 9.3.3 Product benchmarking
- 9.3.4 Strategic initiatives
- 9.4 Horizon Discovery Group plc
- 9.4.1 Company overview
- 9.4.2 Financial performance
- 9.4.3 Product benchmarking
- 9.4.4 Strategic initiatives
- 9.4.5 SWOT analysis
- 9.5 Crown Bioscience Inc.
- 9.5.1 Company overview
- 9.5.2 SWOT analysis
- 9.5.3 Product benchmarking
- 9.5.4 Strategic initiatives
- 9.6 Promega Corporation
- 9.6.1 Company overview
- 9.6.2 SWOT analysis
- 9.6.3 Product benchmarking
- 9.6.4 Strategic initiatives
- 9.7 HD Biosciences Co. Ltd.
- 9.7.1 Company overview
- 9.7.2 SWOT analysis
- 9.7.3 Product benchmarking
- 9.7.4 Strategic initiatives
- 9.8 BPS Biosciences Inc.
- 9.8.1 Company overview
- 9.8.2 SWOT analysis
- 9.8.3 Product benchmarking
- 9.8.4 Strategic initiatives
- 9.9 Gen script Biotech Corporation
- 9.9.1 Company overview
- 9.9.2 Financial performance
- 9.9.3 Product benchmarking
- 9.9.4 Strategic initiatives
- 9.9.5 SWOT analysis
- 9.10 Celentyx Ltd.
- 9.10.1 Company overview
- 9.10.2 SWOT analysis
- 9.10.3 Product benchmarking
- 9.10.4 Strategic initiatives
- 9.11 ImmuneXperts SA
- 9.11.1 Company overview
- 9.11.2 SWOT analysis
- 9.11.3 Product benchmarking
- 9.11.4 Strategic initiatives
- 9.12 Personalis
- 9.12.1 Company overview
- 9.12.2 Product benchmarking
- 9.12.3 Strategic initiatives
- 9.12.4 SWOT analysis
- 9.13 STC Biologics
- 9.13.1 Company overview
- 9.13.2 SWOT analysis
- 9.13.3 Product benchmarking
- 9.13.4 Strategic initiatives
- 9.14 Molecular Imaging Inc. (MI Bioresearch Inc.)
- 9.14.1 Company overview
- 9.14.2 SWOT analysis
- 9.14.3 Product benchmarking
- 9.14.4 Strategic initiatives
- 9.15 Covance, Inc.
- 9.15.1 Company overview
- 9.15.2 Financial performance
- 9.15.3 Product benchmarking
- 9.15.4 Strategic initiatives
- 9.15.5 Swot analysis
